Compare Ares Capital Corporation (ARCC) vs Axogen Inc (AXGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Axogen Inc — how do they compare? Ares Capital Corporation trades at $19.88 (market cap $14.34B), while Axogen Inc trades at $49.77 (market cap $2.61B). The key difference: Ares Capital Corporation is far larger — about 5.5× Axogen Inc's market cap, and Ares Capital Corporation pays a 9.61% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| ARCC | AXGN | |
|---|---|---|
Market Cap | $14.34B | $2.61B |
Sector | Financials | Technology |
52-Week High | $22.68 | $48.48 |
52-Week Low | $17.45 | $14.16 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $2.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.875, down 0.53% on the day, with strong analyst support showing 24 buy ratings and a consensus price target of $19.63. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though oscillators indicate some near-term pressure. Recent earnings showed Q2 2026 EPS of $0.47, slightly below expectations, while the company continues its 17-year dividend streak with consistent $0.48 quarterly payments.
The outlook remains positive with solid fundamentals including 81.77% net income margin and 6.88% ROE, though investors should monitor declining revenue trends from $1.7B in 2024 to projected $1.2B in 2026. Key risks include private credit market strain and dividend coverage tightening to 104%, while institutional confidence remains high with no sell ratings among 32 analysts covering the stock.
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
